TB-ReFLECT: A Collaborative Effort to Enhance TB Clinical Research Oct 25, 2016 TB-ReFLECT: A Collaborative Effort to Enhance TB Clinical Research TUCSON, Ariz., October 25, 2016 —
October 24, 2016 Advancing Tuberculosis Drug Regimen Development through Innovative Quantitative Translational Pharmacology Methods and Approaches
January 10, 2016 Population-Based Resistance of Mycobacterium Tuberculosis Isolates to Pyrazinamide and Fluoroquinolones: Results from a Multicountry Surveillance Project
C-Path and CDISC Announce Updated Therapeutic Area Standard for TB June 6, 2016 C-Path and CDISC Announce Updated Therapeutic Area Standard for TB TUCSON, Ariz., and AUSTIN, Texas –
January 4, 2016 Host-Directed Therapies for Infectious Diseases: Current Status, Recent Progress, and Future Prospects
January 4, 2016 Tuberculosis–Advances in Development of New Drugs, Treatment Regimens, Host-Directed Therapies, and Biomarkers
Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development
CPTR’s Relational Sequencing TB Data Platform (ReSeqTB) is highlighted on pages 59 and 60 of UNITAID’s “2015 Tuberculosis Diagnostics Technology and Market Landscape” report.
